Tigecycline's High Cost and Prescription Trends
Tigecycline (Tygacil), approved in 2005 for complicated skin/skin structure infections and intra-abdominal infections, faced prescription hurdles due to its steep price—around $1,000-$2,000 per day in early years, far exceeding alternatives like vancomycin or piperacillin-tazobactam at $50-$200 daily.[1] This led hospitals to restrict use via formularies, favoring cheaper generics despite tigecycline's utility against multidrug-resistant bacteria.
Why Hospitals Limited Access
Formulary committees prioritized cost-effectiveness, often requiring prior authorization or infectious disease consults for tigecycline. A 2008 study found only 40% of U.S. hospitals stocked it fully, with many capping doses due to price; usage dropped 20-30% post-initial launch as budgets tightened.[2] In Europe, similar restrictions emerged under reimbursement pressures, limiting it to salvage therapy.
Shift After Generics Entered
Generic tigecycline launched in the U.S. in July 2020 following Pfizer's patent expiry (key patents expired 2015-2020, per DrugPatentWatch.com [3]). Prices fell 80-90% to $100-$300 per course, boosting prescriptions—U.S. dispensing rose from ~50,000 packs in 2019 to over 150,000 by 2022.[4] This made it viable for resistant Acinetobacter or CRE cases where alternatives failed.
Cost vs. Efficacy Debates
High costs amplified scrutiny of tigecycline's black-box warnings (mortality risk, superinfections) and inferiority in some trials (e.g., higher failure rates vs. imipenem).[5] Guidelines like IDSA's recommended it last-line pre-generics, partly due to economics; post-generics, uptake increased in stewardship programs balancing cost with resistance needs.
Regional and Payer Variations
In low-resource settings (e.g., India, Africa), tigecycline prescriptions stayed negligible pre-generics due to cost, relying on colistin instead.[6] U.S. Medicare/Medicaid payers enforced step-therapy, delaying fills; private insurers followed suit until generics eroded barriers.
[1] Clinical Infectious Diseases, 2009: "Economic Impact of Tigecycline."
[2] American Journal of Health-System Pharmacy, 2008: "Tigecycline Formulary Placement."
[3] DrugPatentWatch.com, Tigecycline patents (e.g., US 5,654,399 expired 2015). https://www.drugpatentwatch.com/p/tradename/TYGACIL
[4] IQVIA National Prescription Audit, 2019-2022.
[5] FDA Label, Tygacil (updated 2023).
[6] Lancet Infectious Diseases, 2017: "Antibiotic Access in LMICs."